Customer Application (system support)
Promega's AluQuant* Human DNA Quantitation System Automated on the Beckman Coulter Biomek® 2000 Laboratory Workstation
Promega Corporation – www.promega.com
Beckman Coulter and Promega have teamed up to provide automated sample preparation for DNA typing to the forensic community. The solution pairs Promega's new DNA IQ* DNA Isolation System and AluQuant Human DNA Quantitation System with the Biomek 2000.
The uniqueness of the AluQuant Human DNA Quantitation System stems from its use of DNA probes, which are specific to human DNA repeat sequences, and does not require target immobilization or washing steps. This system uses probes that are specific to repetitive human elements allowing quantitation without PCR* amplification. The AluQuant Human DNA Quantitation System has been shown to be unaffected by the presence of DNA from other species even when the DNA is twenty times the amount of the human DNA.
Promega's AluQuant quantitates the amount of human DNA within forensic samples by employing a series of enzymatic reactions that produce a light signal. The signal is read by a luminometer and is proportional to the amount of human DNA present in a sample, which is then compared to a known standard to calculate the quantity of human DNA.
We have developed configurations of the Biomek 2000 Laboratory Automation Workstation specifically for the automation of the DNA IQ and AluQuant Systems. The Biomek 2000 automates the pipetting, magnetic separation, heating and shaking/mixing steps of the protocols, improving performance and productivity.
Features
- Solution-based chemistry does not require gel electrophoresis or blotting steps
- Luminometer provides true quantitative and reproducible information
- No interference from non-human DNA
- Probes are specific for highly repeated regions of human DNA making quantitation possible without PCR
- Broad quantitation range from 0.1ng to 50ng
- Quantitation not affected by degraded DNA
* All trademarks are the property of their respective owners. Where applicable, the PCR process is covered by patents owned by Roche Molecular Systems, Inc., and F. Hoffman-LaRoche, Ltd.
